Technical Articles

Though anti - tumor immune responses are activated, dormant disseminated tumor cells (DTCs) can still survive long - term. The specific mechanisms of how they escape immune surveillance remain unclear. This article introduces a study published in Cancer Cell Metabolism (IF = 50.3) in January 2025. It reveals a newly - recognized immune evasion paradigm - the "relative rarity" effect - which is the pathological basis for the persistence of DTCs.